Clinical trial
A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who…
NCT00160524 · UCB Pharma SA, Industry · Completed
Key facts
| NCT number | NCT00160524 |
|---|---|
| Title | A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] |
| Official title | A Phase III Multi-national, Multi-centre, Open Label, Safety Study to Assess the Safety of Chronic Therapy With the Humanised Anti-TNF PEG Conjugate CDP870 400 mg sc, (Dosed 4-weekly), in the Treatment of Patients With Active Crohn's Disease Who Have Previously Completed Studies CDP870-031 or… |
| Acronym | PRECiSE 3 |
| Lead sponsor | UCB Pharma SA, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Crohn's Disease |
| Intervention type | Biological |
| Interventions | Certolizumab Pegol (CDP870) |
| Enrollment | 596 |
| Start date | Jul 1, 2004 |
| Primary completion | Aug 1, 2012 |
| Completion | Aug 1, 2012 |
| First posted | Sep 12, 2005 |
| Last update posted | Aug 1, 2018 |
| Countries | Australia, Austria, Belarus, Belgium, Bulgaria, Canada, Czechia, Denmark, Estonia, Georgia, Germany, Hong Kong and 17 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: